MaxCyte, Inc. Proceeds from Stock Options Exercised
MaxCyte, Inc. (MXCT) reported Proceeds from Stock Options Exercised of $29.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromStockOptionsExercised · last filed 2026-08-13
- MaxCyte, Inc. proceeds from stock options exercised for the quarter ending 2026-06-30 was $24.00K, a 20.00% increase year-over-year.
- MaxCyte, Inc. proceeds from stock options exercised for the quarter ending 2026-03-31 was $5.00K, a 98.69% decline year-over-year.
- MaxCyte, Inc. proceeds from stock options exercised for the quarter ending 2025-12-31 was $15.00K, a 93.12% decline year-over-year.
- MaxCyte, Inc. proceeds from stock options exercised for the quarter ending 2025-09-30 was $14.00K, a 93.86% decline year-over-year.
- MaxCyte, Inc. proceeds from stock options exercised for fiscal 2025 was $432.00K, a 72.95% decline from fiscal 2024.
- MaxCyte, Inc. proceeds from stock options exercised for fiscal 2024 was $1.60M, a 14.78% decline from fiscal 2023.
- MaxCyte, Inc. proceeds from stock options exercised for fiscal 2023 was $1.87M, a 35.11% decline from fiscal 2022.
- MaxCyte, Inc. proceeds from stock options exercised for fiscal 2022 was $2.89M, a 20.47% decline from fiscal 2021.
| Period end | Proceeds from Stock Options Exercised 3 month | Proceeds from Stock Options Exercised 3 month as first filed | Proceeds from Stock Options Exercised 6 month | Proceeds from Stock Options Exercised 6 month as first filed | Proceeds from Stock Options Exercised 9 month | Proceeds from Stock Options Exercised 12 month | Proceeds from Stock Options Exercised 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $24.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $29.00K 10-Q · filed 2026-08-13 | $44.00K derived: sum of 3 quarters · filed 2026-08-13 | $58.00K derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2026-03-31 | $5.00K 10-Q · filed 2026-05-13 | $20.00K derived: sum of 2 quarters · filed 2026-05-13 | $34.00K derived: sum of 3 quarters · filed 2026-05-13 | $54.00K derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-12-31 | $15.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $29.00K derived: sum of 2 quarters · filed 2026-03-25 | $49.00K derived: sum of 3 quarters · filed 2026-08-13 | $432.00K 10-K · filed 2026-03-25 | |||
| 2025-09-30 | $14.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $34.00K derived: sum of 2 quarters · filed 2026-08-13 | $417.00K 10-Q · filed 2025-11-13 | $635.00K derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-06-30 | $20.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $403.00K 10-Q · filed 2026-08-13 | $621.00K derived: sum of 3 quarters · filed 2026-08-13 | $849.00K derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-03-31 | $383.00K 10-Q · filed 2026-05-13 | $601.00K derived: sum of 2 quarters · filed 2026-05-13 | $829.00K derived: sum of 3 quarters · filed 2026-05-13 | $1.28M derived: sum of 4 quarters · filed 2026-05-13 | |||
| 2024-12-31 | $218.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $446.00K derived: sum of 2 quarters · filed 2026-03-25 | $894.00K derived: sum of 3 quarters · filed 2026-03-25 | $1.60M 10-K · filed 2026-03-25 | |||
| 2024-09-30 | $228.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $676.00K derived: sum of 2 quarters · filed 2025-11-13 | $1.38M 10-Q · filed 2025-11-13 | $1.60M derived: sum of 4 quarters · filed 2025-11-13 | |||
| 2024-06-30 | $448.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $1.15M 10-Q · filed 2025-08-06 | $1.38M derived: sum of 3 quarters · filed 2025-08-06 | $1.41M derived: sum of 4 quarters · filed 2025-08-06 | |||
| 2024-03-31 | $703.00K 10-Q · filed 2025-05-08 | $927.00K derived: sum of 2 quarters · filed 2025-05-08 | $964.00K derived: sum of 3 quarters · filed 2025-05-08 | $1.12M derived: sum of 4 quarters · filed 2025-05-08 | |||
| 2023-12-31 | $224.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $261.00K derived: sum of 2 quarters · filed 2025-03-11 | $418.00K derived: sum of 3 quarters · filed 2025-03-11 | $1.87M 10-K · filed 2025-03-11 | |||
| 2023-09-30 | $37.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $194.00K derived: sum of 2 quarters · filed 2024-11-06 | $1.65M 10-Q · filed 2024-11-06 | $2.88M derived: sum of 4 quarters · filed 2024-11-06 | |||
| 2023-06-30 | $157.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $1.61M 10-Q · filed 2024-08-06 | $1.61M 10-Q · filed 2023-08-09 | $2.84M derived: sum of 3 quarters · filed 2024-08-06 | $3.28M derived: sum of 4 quarters · filed 2024-08-06 | ||
| 2023-03-31 | $1.46M 10-Q · filed 2024-05-07 | $1.46M 10-Q · filed 2023-05-10 | $2.68M derived: sum of 2 quarters · filed 2024-05-07 | $3.13M derived: sum of 3 quarters · filed 2024-05-07 | $3.45M derived: sum of 4 quarters · filed 2024-05-07 | ||
| 2022-12-31 | $1.23M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $1.67M derived: sum of 2 quarters · filed 2024-03-12 | $2.00M derived: sum of 3 quarters · filed 2024-03-12 | $2.89M 10-K · filed 2024-03-12 | $2.89M 10-K · filed 2023-03-15 | ||
| 2022-09-30 | $444.40K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $769.90K derived: sum of 2 quarters · filed 2023-11-08 | $1.66M 10-Q · filed 2023-11-08 | $2.87M derived: sum of 4 quarters · filed 2023-11-08 | |||
| 2022-06-30 | $325.50K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $1.22M 10-Q · filed 2023-08-09 | $2.43M derived: sum of 3 quarters · filed 2023-08-09 | $2.76M derived: sum of 4 quarters · filed 2023-08-09 | |||
| 2022-03-31 | $892.60K 10-Q · filed 2023-05-10 | $2.10M derived: sum of 2 quarters · filed 2023-05-10 | $2.43M derived: sum of 3 quarters · filed 2023-05-10 | $2.49M derived: sum of 4 quarters · filed 2023-05-10 | |||
| 2021-12-31 | $1.21M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $1.54M derived: sum of 2 quarters · filed 2023-03-15 | $1.59M derived: sum of 3 quarters · filed 2023-03-15 | $3.63M 10-K · filed 2023-03-15 | |||
| 2021-09-30 | $334.70K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $386.90K derived: sum of 2 quarters · filed 2022-11-09 | $2.42M 10-Q · filed 2022-11-09 | $2.54M derived: sum of 4 quarters · filed 2022-11-09 | |||
| 2021-06-30 | $52.20K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $2.09M 10-Q · filed 2022-08-10 | $2.20M derived: sum of 3 quarters · filed 2022-08-10 | ||||
| 2021-03-31 | $2.04M 10-Q · filed 2022-05-09 | $2.15M derived: sum of 2 quarters · filed 2022-05-09 | |||||
| 2020-12-31 | $115.10K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-22 | $401.00K 10-K · filed 2022-03-22 | |||||
| 2020-09-30 | $285.90K 10-Q · filed 2021-11-10 | ||||||
| 2019-12-31 | $132.70K 10-K · filed 2022-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |